Dupilumab Shows Benefit for Those With Severe Asthma During Clinical Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 investigational study evaluating dupilumab in adults and adolescents with severe, steroid-dependent asthma met its primary endpoint and key secondary endpoints. … lesen Sie weiter! Quelle: : http://feedproxy.google.com/~r/asthma-allergy/~3/Q1SDpIHAYCg/dupilumab-shows-benefit-for-those-with-severe-asthma-during-clinical-trial